# Orca Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orca-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Abingdon, UK
- Website: www.orcapharmaceuticals.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Mar 18, 2014)
- Investors on record: 2

## About

Orca Pharmaceuticals is a UK-based biopharmaceutical company dedicated to advancing healthcare solutions through innovative drug development and distribution. The company specializes in providing a range of pharmaceutical products targeting men's and women's health issues.Founded in 2012 in Abingdon, UK, Orca Pharmaceuticals focuses on developing and supplying specialized pharmaceutical products. The company has undergone strategic pivots to enhance its operational framework. Yasser Hammad, the founder, has a history of entrepreneurship in the pharmaceutical sector. Orca Pharmaceuticals raised USD 1.3 mn in Seed funding from BioMotiv on April 28, 2014, marking its total fundraising to USD 1.3 mn across 2 deals.Orca Pharmaceuticals offers a variety of medications through its online pharmacy, including prescription and over-the-counter solutions primarily focusing on men's and women's health issues. The core offerings encompass treatments for erectile dysfunction, hormonal therapies, and other specialized health needs, ensuring convenient access to essential medications for a diverse customer base across multiple European countries.Revenue at Orca Pharmaceuticals is generated through direct-to-consumer sales of pharmaceutical products via its online platform. The company’s revenue model is based on individual sales of prescription medications and health supplements, emphasizing competitive pricing to attract and retain customers. While specific pricing details are not disclosed, affordability is highlighted as a core feature of its service offerings, targeting various consumers in need of accessible healthcare products.Orca Pharmaceuticals aims to leverage its recent Seed funding of USD 1.3 mn to enhance its product line and expand into new geographic markets. Plans are in place to introduce new pharmaceutical products designed to address emerging health needs. The company is targeting specific markets in Europe for expansion by 2025, ensuring broader access to its innovative healthcare solutions.

## Funding rounds

- Seed, Mar 18, 2014, $1.2M — NYU Venture Capital, BioMotiv

## Investors

- NYU Venture Capital (https://capitalatlas.ai/funds/nyu-venture-capital) — Seed
- BioMotiv — Seed